Cliff Gross

And of course, when we're engaged by a client, they give us the theme that they're interested in looking at properties for.

What we do is we have 60 science advisors and different verticals that do the initial due diligence on properties that are of interest to us.

And then we have another business called Invention Evaluator that assesses the market potential of those discoveries.

And then we make a decision like any investment committee would as to whether or not we want to acquire the rights to those properties and commercialize them.

There's a couple, actually.

One of them is making food healthier.

And we've acquired a couple of really neat technologies in that sector.

From what university?

One was from the University of Arkansas.

we've acquired two technologies.

One is actually a new form of salt, a new way of manufacturing table salt that has, in the table salt version of it, it has 78% less sodium, so it's healthier for the users.

And then another area that we're keen on is augmented reality.

We've acquired a portfolio of 13 optics patents from the University of Central Florida,

that allow you to make free-form optics designs in glasses that are lightweight, not bulky, and should look like normal glasses.

So we're very keen on augmented reality.

We use a forward revenue share.

relatively inexpensively upfront and then share a percentage of the success down the road with the institution.

We wouldn't say for free, but for a modest price.

And then if we are successful in commercializing them, it will be a win for us as well as for the research institution and the faculty members that worked on the idea.

Yeah, royalties are correct.